Samuel A. WaxmanSamuel A.Waxman

Apertura Gene Therapy, in its $67 million Series A financing and its foundational in-licenses from The Broad Institute of MIT and Harvard and Harvard Medical School.

Loadsmart, a leading freight technology company, in its $200 million Series D financing.

Galway Sustainable Credit, in its $250 million investment by funds managed by Macquarie Asset Management.

Neomorph, in its $109 million Series A financing to advance a proprietary targeted protein degradation platform and specific programs.

Jaguar Gene Therapy in connection with its $139 million Series B funding co-led by Eli Lilly and Company and Deerfield Management.

Clearview AI, a leading facial recognition company, in connection with its $30 million Series B financing.

Deerfield Management, in connection with its early-stage therapeutic research partnerships with various elite academic institutions including The Broad Institute of MIT and Harvard, Johns Hopkins University, Harvard University, and the Dana Farber Cancer Institute.

Merck & Co. in connection with various strategic alliance transactions.

Orchestra BioMed, in connection with its strategic collaborations with Medtronic and Terumo.

Canopy Growth Corporation, in connection with various M&A transactions.

Cresco Labs, in connection with various M&A transactions.

The Scotts Miracle-Gro Company, in connection with various M&A transactions.

RIV Capital, in connection with various investment transactions.

Turning Point Brands, in connection with various debt and minority equity investments.